Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: A TRITON-TIMI 38 subgroup analysis (Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38)

JACC: Cardiovascular Interventions

Volumn 7, Issue 6, 2014, Pages 604-612

  Udell, Jacob A ^a   Braunwald, Eugene ^b   Antman, Elliot M ^b   Murphy, Sabina A ^b   Montalescot, Gilles ^c   Wiviott, Stephen D ^b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

antiplatelet therapy; myocardial infarction; periprocedural myocardial injury; prasugrel; primary percutaneous coronary intervention

Indexed keywords

CLOPIDOGREL; PRASUGREL; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYMPTOM; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; ELECTROCARDIOGRAPHY; FIBRINOLYTIC THERAPY; FOLLOW UP; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; PROSPECTIVE STUDY; TIME;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; THROMBOLYTIC THERAPY; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902822333     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.01.160     Document Type: Article

References (25)

1. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
2. P.G. Steg, S.K. James, and D. Atar et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Eur Heart J 33 2012 2569 2619
3. K.A. Fox, P.G. Steg, and K.A. Eagle et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006 JAMA 297 2007 1892 1900
4. J.-P. Bassand, N. Danchin, and G. Filippatos et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology Eur Heart J 26 2005 2733 2741
5. N. Danchin, E. Durand, and D. Blanchard Pre-hospital thrombolysis in perspective Eur Heart J 29 2008 2835 2842
6. S.D. Wiviott, E. Braunwald, and C.H. McCabe et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
7. G. Montalescot, S.D. Wiviott, and E. Braunwald et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
8. S.D. Wiviott, E.M. Antman, and C.M. Gibson et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) Am Heart J 152 2006 627 635
9. D.E. Cutlip, S. Windecker, and R. Mehran et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
10. K. Thygesen, J.S. Alpert, and A.S. Jaffe et al. Third universal definition of myocardial infarction J Am Coll Cardiol 60 2012 1581 1598
11. D.A. Morrow, S.D. Wiviott, and H.D. White et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction Circulation 119 2009 2758 2764
12. M.P. Bonaca, S.D. Wiviott, and E. Braunwald et al. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) Circulation 125 2012 577 583
13. E.M. Antman, and D.A. Morrow Biomarker release after percutaneous coronary intervention Circ Cardiovasc Interv 1 2008 3 6
14. A.J. Lansky, and G.W. Stone Periprocedural myocardial infarction: prevalence, prognosis, and prevention Circ Cardiovasc Interv 3 2010 602 610
15. G.G. Babu, J.M. Walker, D.M. Yellon, and D.J. Hausenloy Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection Eur Heart J 32 2011 23 31
16. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury N Engl J Med 357 2007 1121 1135
17. E.M. Jolicoeur, and J.F. Tanguay From primary to secondary percutaneous coronary intervention: the emerging concept of early mechanical reperfusion with delayed facilitated stenting-when earlier may not be better Can J Cardiol 27 2011 529 533
18. W.L. Miller, K.N. Garratt, M.F. Burritt, G.S. Reeder, and A.S. Jaffe Timing of peak troponin T and creatine kinase-MB elevations after percutaneous coronary intervention Chest 125 2004 275 280
19. A.S. Jaffe, F.S. Apple, B. Lindahl, C. Mueller, and H.A. Katus Why all the struggle about CK-MB and PCI? Eur Heart J 33 2012 1046 1048
20. B.S. Lewis, S.R. Mehta, and K.A. Fox et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Am Heart J 150 2005 1177 1184
21. M.S. Sabatine, C.P. Cannon, and C.M. Gibson et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study JAMA 294 2005 1224 1232
22. C.M. Gibson, S.A. Murphy, and Y.B. Pride et al. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study Am Heart J 155 2008 133 139
23. G. Montalescot, L. Bolognese, and D. Dudek et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes N Engl J Med 369 2013 999 1010
24. L. Wallentin, R.C. Becker, and A. Budaj et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
25. P.G. Steg, S. James, and R.A. Harrington et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141